Published in Expert Rev Clin Immunol on January 01, 2015
Dissecting Kawasaki disease: a state-of-the-art review. Eur J Pediatr (2017) 0.92
Pneumonia, Acute Respiratory Distress Syndrome, and Early Immune-Modulator Therapy. Int J Mol Sci (2017) 0.80
The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart. J Immunol Res (2016) 0.77
Found in Translation: International initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki Disease. Arthritis Rheumatol (2016) 0.77
Whole genome sequencing of an African American family highlights toll like receptor 6 variants in Kawasaki disease susceptibility. PLoS One (2017) 0.75
miR-483 Targeting of CTGF Suppresses Endothelial-to-Mesenchymal Transition: Therapeutic Implications in Kawasaki Disease. Circ Res (2016) 0.75
The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease? Korean Circ J (2017) 0.75
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol (2001) 12.00
A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics (1974) 9.97
Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol (2005) 9.91
The regulation of IL-10 production by immune cells. Nat Rev Immunol (2010) 9.18
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity (2009) 9.01
Origin of regulatory T cells with known specificity for antigen. Nat Immunol (2002) 7.49
A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med (1991) 5.76
In vivo instruction of suppressor commitment in naive T cells. J Exp Med (2004) 5.47
Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol (2009) 4.90
Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol (2007) 4.55
The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med (1986) 4.49
High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet (1981) 4.39
Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol (2009) 4.07
Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 3.80
IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest (2004) 3.69
Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med (2001) 3.10
Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol (1996) 2.18
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet (2011) 1.97
The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics (1995) 1.93
Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol (2009) 1.84
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood (2007) 1.83
Gene expression profiling of the effect of high-dose intravenous Ig in patients with Kawasaki disease. J Immunol (2005) 1.81
Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood (2006) 1.80
Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet (2012) 1.65
A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet (2012) 1.58
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol (2008) 1.35
Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol (2011) 1.24
Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity (2010) 1.12
CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function. J Exp Med (2010) 1.03
Functional FCGR2B gene variants influence intravenous immunoglobulin response in patients with Kawasaki disease. J Allergy Clin Immunol (2011) 1.03
Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity (2014) 0.92
The role of TGF-β and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol (2012) 0.92
High-dose intravenous gammaglobulin for Kawasaki disease. Lancet (1983) 0.91
Inhibition of FcγR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcγRIIb in human macrophages. Blood (2014) 0.88
Endoplasmic reticulum stress drives a regulatory phenotype in human T-cell clones. Cell Immunol (2010) 0.85
Effect of high doses of intravenously administered immune globulin on natural killer cell activity in peripheral blood. J Pediatr (1992) 0.85
A genetic variant rs1801274 in FCGR2A as a potential risk marker for Kawasaki disease: a case-control study and meta-analysis. PLoS One (2014) 0.85
Immunology. Immunity benefits from a little suppression. Science (2008) 0.83
High-density genotyping of immune loci in Kawasaki disease and IVIG treatment response in European-American case-parent trio study. Genes Immun (2014) 0.82
Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol (2013) 0.81
Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. Autoimmunity (2015) 0.77
TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood (2005) 1.09
Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas. J Exp Med (2004) 1.00
Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol (2005) 0.99
Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr (2012) 0.98
Treatment response in Kawasaki disease is associated with sialylation levels of endogenous but not therapeutic intravenous immunoglobulin G. PLoS One (2013) 0.94
The role of TGF-β and myofibroblasts in the arteritis of Kawasaki disease. Hum Pathol (2012) 0.92
Analysis of SCA8 and SCA12 loci in 134 Italian ataxic patients negative for SCA1-3, 6 and 7 CAG expansions. J Neurol (2002) 0.83
Neuropsychological picture of 33 spinocerebellar ataxia cases. J Clin Exp Neuropsychol (2011) 0.79
Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease. Autoimmunity (2015) 0.77